BETA-BLOCKER THERAPY AFTER MYOCARDIAL INFARCTION IN PATIENTS WITHOUT HEART FAILURE: A META-ANALYSIS OF RANDOMIZED CONTROLLED TRIALS

Clicks: 7
ID: 331078
2026
Free PDF
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This article has not been analysed, so there is no overall score — reader engagement is measured and shown alongside.
AI Quality Assessment
Not analyzed
Readership in this journal
Emerging

Ranked #327 of 330 articles by views in European heart journal supplements : journal of the European Society of Cardiology

Most read Least read

Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 330 in total.

Mint this article as an NFT
Not yet minted

Create a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.

5 SUSD one-off · no wallet required
Sign in to mint
Abstract
Abstract Background and Aims Beta-blocker (BB) therapy after myocardial infarction (MI) in patients with reduced left ventricular ejection fraction (LVEF) is well established. However, recent randomised controlled trials (RCTs) in post-MI patients without significantly impaired LVEF have yielded conflicting results. This meta-analysis aimed to synthesise pooled evidence from high-quality RCTs to clarify the role of BB therapy in this population. Methods A systematic literature search was conducted across major scientific databases until 1 April 2026 for RCTs comparing long-term oral BB therapy against no BB in post-MI patients with LVEF ≥40%. The primary outcome was major adverse cardiovascular events (MACE), defined as a composite of all-cause mortality, MI or acute coronary syndrome, or hospitalisation for heart failure. A random-effects model using the Mantel-Haenszel method was used to pool risk ratios (RR) and 95% confidence intervals (CI), with heterogeneity assessed using the I² statistic. Results Six RCTs (CAPITAL-RCT, REDUCE-AMI, ABYSS, REBOOT-CNIC, BETAMI-DANBLOCK, and SMART-DECISION) were included, encompassing 11,698 patients in the BB group and 11,770 in the no-BB group. BB therapy was not associated with a significant reduction in MACE compared to no BB therapy (RR 0.96, 95% CI 0.87–1.05; I² = 31.0%; p = 0.203), with a prediction interval of 0.78–1.18. Conclusion This updated meta-analysis, incorporating the recently published SMART-DECISION trial, found that routine BB therapy in post-MI patients without significantly impaired LVEF does not reduce MACE. These findings challenge universal BB prescription in this population, where historical benefits may be attenuated by contemporary secondary prevention strategies.Figure 1.Pooled analysis of beta-blocker versus no beta-blocker therapy for major adverse cardiovascular events in post-myocardial infarction patients without reduced ejection fraction, incorporating six randomised controlled trials including the updated SMART-DECISION trial (2026).
Reference Key
openalex_W7220392817 Use this key to autocite in the manuscript while using SciMatic Manuscript Manager or Thesis Manager
Authors I F Arba, A Primiputri, M B A Paramarta, C E C Z Multazam
Are you one of these authors? Claim your profile
Journal European heart journal supplements : journal of the European Society of Cardiology
Year 2026
DOI
10.1093/eurheartjsupp/suag119.034
URL
https://doi.org/10.1093/eurheartjsupp/suag119.034
Keywords Keywords not found

Citations

No citations found. To add a citation, contact the admin at info@scimatic.org

Comments

No comments yet. Be the first to comment on this article.